Literature DB >> 16288182

Plasma substitutes.

J Boldt1, S Suttner.   

Abstract

Adequate restoration of intravascular volume remains an important therapeutic manoeuvre in managing the surgical, medical and the critically ill intensive care patient. Definition of the ideal volume replacement strategy still remains one of the burning problems. The choice between colloid and crystalloid solutions continues to generate controversy. The highly controversial crystalloid/colloid dispute has been enlarged to a colloid/colloid debate because aside of the natural colloid albumin several non-protein (synthetic) colloids are available as plasma substitutes (e.g. dextrans, gelatins, hydroxyethyl starch [HES] solutions). Due to their varying physico-chemical properties, these solutions widely differ with regard to their pharmacokinetic and pharmacodynamic properties as well as to their hemodynamic efficacy and side-effects. HES is the most intensively studied plasma substitute. The different HES preparations are defined by concentration, molar substitution (MS), mean molecular weight (MW), and the C2/C6 ratio of substitution. Two new HES specification, a third-generation HES with a lower Mw and a lower MS (6% HES 130/0.4) than all other HES preparation and a first-generation HES prepared in a balanced solution, may be promising by improving the therapy of the hypovolemic patient. Albumin cannot be recommended for correction of hypovolemia because of ist extreme costs and because it can easily be replaced by other no-protein colloids. Dextrans should also not be used any more due to the negative effects on coagulation and its high anaphylactic potency. The historical crystalloid/colloid controversy has been focused primarily on outcome. There is increasing evidence that outcome (mortality) is not the correct measure when assessing the ideal volume replacement strategy. New concepts about critical care such as organ perfusion and organ function, the role of inflammation, immunological aspects, and wound healing may change this point of view. Volume replacement has been hitherto often based on art, dogma and personal beliefs. Further well-performed studies in this area will help more to shed new light on the ideal volume replacement strategy of the hypovolemic patient than more meta-analyses that are pooling old-to-very old studies to solve this problem.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16288182

Source DB:  PubMed          Journal:  Minerva Anestesiol        ISSN: 0375-9393            Impact factor:   3.051


  12 in total

1.  Plasma volume expansion of 5% albumin, 4% gelatin, 6% HES 130/0.4, and normal saline under increased microvascular permeability in the rat.

Authors:  Maris Dubniks; Johan Persson; Per-Olof Grände
Journal:  Intensive Care Med       Date:  2006-11-21       Impact factor: 17.440

Review 2.  Are renal adverse effects of hydroxyethyl starches merely a consequence of their incorrect use?

Authors:  Christiane S Hartog; Frank M Brunkhorst; Christoph Engel; Andreas Meier-Hellmann; Maximilian Ragaller; Tobias Welte; Evelyn Kuhnt; Konrad Reinhart
Journal:  Wien Klin Wochenschr       Date:  2011-03-01       Impact factor: 1.704

3.  Hemorheological implications of perfluorocarbon based oxygen carrier interaction with colloid plasma expanders and blood.

Authors:  Diana M Vásquez; Daniel Ortiz; Oscar A Alvarez; Juan C Briceño; Pedro Cabrales
Journal:  Biotechnol Prog       Date:  2013-04-18

4.  The risk associated with hyperoncotic colloids in patients with shock.

Authors:  Frédérique Schortgen; Emmanuelle Girou; Nicolas Deye; Laurent Brochard
Journal:  Intensive Care Med       Date:  2008-08-07       Impact factor: 17.440

5.  The impact of crystalloid and colloid infusion on the kidney in rodent sepsis.

Authors:  Martin Alexander Schick; Tobias Jobst Isbary; Nicolas Schlegel; Juergen Brugger; Jens Waschke; Ralf Muellenbach; Norbert Roewer; Christian Wunder
Journal:  Intensive Care Med       Date:  2009-11-05       Impact factor: 17.440

6.  Assessment of coagulation with 6% hydroxyethyl starch 130/0.4 in cesarean section.

Authors:  Chung-Sik Oh; Tae-Yun Sung; Seong-Hyop Kim; Duk-Kyung Kim; Jeong-Ae Lim; Nam-Sik Woo
Journal:  Korean J Anesthesiol       Date:  2012-04-23

7.  Colloid-induced kidney injury: experimental evidence may help to understand mechanisms.

Authors:  Frédérique Schortgen; Laurent Brochard
Journal:  Crit Care       Date:  2009-04-03       Impact factor: 9.097

8.  The impact of 30 ml/kg hydroxyethyl starch 130/0.4 vs hydroxyethyl starch 130/0.42 on coagulation in patients undergoing abdominal surgery.

Authors:  Chryssoula Staikou; Anteia Paraskeva; Argyro Fassoulaki
Journal:  Indian J Med Res       Date:  2012-09       Impact factor: 2.375

Review 9.  Pro/con debate: should synthetic colloids be used in patients with septic shock?

Authors:  James Downar; Stephen E Lapinsky
Journal:  Crit Care       Date:  2009-01-29       Impact factor: 9.097

10.  The predictability of dynamic preload indices depends on the volume of fluid challenge: A prospective observational study in the operating theater.

Authors:  Pierre-Grégoire Guinot; Julien Marc; Bruno de Broca; Thomas Archange; Stéphane Bar; Osama Abou-Arab; Hervé Dupont; Marc-Olivier Fischer; Emmanuel Lorne
Journal:  Medicine (Baltimore)       Date:  2018-10       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.